Physician profile
Sunil Savarirayan
NPI 1497711964
$2,205.74
in general payments reported to CMS, 2019-2025
23 companies · $33.22 in 2025
The $33.22 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $333 · 2021: $542 · 2022: $220 · 2023: $14.19 · 2024: $32.95 · 2025: $33.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $723.11 | 2019-2022 | |
| Janssen Biotech, INC. | $271.46 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $216.57 | 2019-2024 | Provenge |
| Pfizer INC. | $191.64 | 2019-2022 | |
| Medtronic USA, INC. | $144.68 | 2019-2020 | |
| Axonics, INC. | $123.37 | 2021-2022 | |
| Myovant Sciences INC. | $76.98 | 2021-2022 | |
| Abbvie INC. | $68.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.88 | 2019 | |
| Metuchen Pharmaceuticals | $47.31 | 2019-2020 | |
| Celgene Corporation | $40.28 | 2022 | |
| Allergan, INC. | $38.63 | 2020-2022 | |
| Procept Biorobotics Corporation | $33.22 | 2025 | |
| Ferring Pharmaceuticals INC. | $27.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.65 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $26.82 | 2021-2022 | |
| Amgen INC. | $15.91 | 2020 | |
| Merck Sharp & Dohme LLC | $15.90 | 2020 | |
| Antares Pharma, INC. | $15.81 | 2022 | |
| Ambu INC. | $14.19 | 2023 | |
| Urogen Pharma, INC. | $13.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.83 | 2021 | |
| Boston Scientific Corporation | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Savarirayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.